Science Daily: Pharmacology News

NOVEMBER 28, 2023

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists -- so far.

Disease 208

Disease Drug Development Therapies Drugs 208

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development?

Therapies 105

Therapies Drug Development Disease Clinical Development 105

Drug Target Review

JANUARY 14, 2025

For more insights, refer to Part 1 of this series, where we explore foundational concepts for early drug discovery workflows. About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries.

Drugs 69

Drugs Protein Expression Science Research 69

SCIENMAG: Medicine & Health

JUNE 14, 2023

Although effective drugs and therapies have been developed for most breast cancer subtypes, triple negative breast cancer lacks the key receptors that these drugs interact with – in other words, it’s negative for the three receptors for which […]

Drug Development 87

Drug Development Drugs Therapies Science 87

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. I opted for medicine due to my love for biological sciences.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Drugs 59

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

DECEMBER 6, 2024

About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries. This iterative nature of scientific investigation often leads to new discoveries as researchers refine their understanding of the data.

RNA 52

RNA Drugs Research Science 52

DrugBank

APRIL 3, 2025

Advances in predictive modeling, high-throughput screening, and omics technologies have provided powerful tools to uncover safety risks early in the drug development pipeline. Historically, many drug candidates have been discontinued during late-stage clinical trials due to unforeseen toxicities.

Drug Development 52

Drug Development Drugs Clinical Trials Pharmacokinetics 52

Drug Target Review

DECEMBER 23, 2024

Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. Wangs research focuses on developing mechanistic mathematical models to quantitatively characterise ADC-induced toxicities.

Research 52

Research Treatment Therapies Drug Development 52

Alta Sciences

JULY 25, 2024

Top 10 Life Science Resources for Summer 2024 pmjackson Thu, 07/25/2024 - 14:44 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Tags Science and Health Weight 16 Read the eBook.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

Drug Target Review

AUGUST 9, 2024

The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.

Science 59

Science Drugs Compliance Drug Development 59

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. 5 Organoids are recognised as New Alternative Methods (NAMs) in drug development.

Clinical Research 116

Clinical Research Research Drug Development Science 116

Alta Sciences

OCTOBER 30, 2023

Top 10 Life Science Resources pmjackson Mon, 10/30/2023 - 16:16 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. Catch up on what you may have missed below! The Altascientist : Issue No. Watch the video.

Science 52

Science Clinical Trials Pharmacokinetics Clinical Pharmacology 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

Science, 2020. With so much information swirling around these days about the coronavirus disease 2019 (COVID-19) pandemic, it would be easy to miss one of the most interesting and significant basic science reports of the past few weeks. Credit: Adapted from Yan R., Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 27 March 2020.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

FDA Law Blog: Drug Discovery

MAY 19, 2024

aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C.

Disease 59

Disease Therapies Drug Development FDA 59

Broad Institute

SEPTEMBER 6, 2023

Diabetes and cardiac fibrosis are two conditions in dire need of new therapies,” said Todd Golub, director of the Broad Institute. For both patient populations, there are no safe and effective therapies for reversing disease. He is also an institute member and director of the Cardiovascular Disease Initiative at the Broad.

Disease 136

Disease Research Therapies Treatment 136

Alta Sciences

NOVEMBER 13, 2024

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.

Clinical Pharmacology 40

Clinical Pharmacology Laboratories Drug Development Pharmaceuticals 40

Drug Target Review

OCTOBER 30, 2024

As we continue to evolve our drug characterisation processes at Verseon, we see the extensive use of assembloids as essential enabling technology for the future of all drug development. 22-26 Technically, these findings could apply to both restoration and enhancement of organ function. 2017;23(1):49-59. 2019;363(6423):126-7.

Treatment 106

Treatment Disease Clinical Trials Research 106

Tebu Bio: Drug Discovery

JULY 4, 2019

Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising technology in cancer therapy and disease treatment.

Drug Development 52

Drug Development Science Therapies Drugs 52

Drug Target Review

FEBRUARY 29, 2024

From a very young age, I was drawn to science and medicine. This early exposure to bench science had a long-lasting impact. Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development.

Therapies 111

Therapies Disease Clinical Trials Science 111

Perficient: Drug Development

SEPTEMBER 22, 2023

With a highly skilled team of Salesforce consultants and developers with Healthcare and Life Sciences (HLS) experience, Perficient is especially interested in this year’s announcements for the vertical. Here are takeaways for Salesforce clients, consultants, and developers working in HLS.

Science 59

Science Clinical Trials Engineering Production 59

Drug Target Review

SEPTEMBER 25, 2024

While these approaches often produce encouraging initial results, the development of drug resistance remains a major obstacle for long-term patient survival. Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

FDA Law Blog: Drug Discovery

JULY 17, 2024

An Opportunity to Leverage the Newly Created Rare Disease Advisory Committee across CDER and CBER In Frank and James’ 2018 proposal there was also a recommendation for the formation of a Rare Disease Advisory Committee, which would allow FDA access to experts in the science of small trials and other aspects of rare disease research.

FDA 105

FDA Disease Clinical Pharmacology Science 105

Drug Target Review

FEBRUARY 19, 2024

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. It was then that I knew I wanted to dedicate my career to science. If you are passionate about science and technology GO FOR IT! BECOME A ROLE MODEL!

Molecular Biology 110

Molecular Biology Science Protein Expression Production 110

KIF1A

SEPTEMBER 30, 2023

Read the Guide FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies One frustrating aspect of traditional drug development, especially for rare disease communities, is the tempo of regulatory decisions on potential drugs.

Disease 111

Disease FDA Clinical Trials Therapies 111

The Pharma Data

SEPTEMBER 14, 2020

Today these medicines, called targeted therapies, are available for treating many forms of cancer. Targeted therapies took center stage when Alice Shaw started her career as a physician-scientist caring for patients with lung cancer. Clinical trial investigators are the eyes and ears in the clinic for pharmaceutical drug developers.

Science 52

Science Clinical Trials Therapies Trials 52

Drug Target Review

NOVEMBER 6, 2023

2 It is this complexity that necessitates powerful, targeted combination therapies. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Conversations in Drug Development Trends

DECEMBER 7, 2023

Despite a rapidly evolving clinical development landscape, we’ve remained grounded in medicine and science, helping sponsors achieve their clinical development goals across a range of therapeutic areas through our ability to adapt to changing client needs, deliver customized study teams, and dedicated scientific expertise.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

The Pharma Data

JANUARY 24, 2021

a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond , Ph.D. as Senior Vice President, Preclinical and Translational Sciences. . VANCOUVER, BC , Jan. 25, 2021 /PRNewswire/ — Notch Therapeutics Inc.,

Science 52

Science Engineering Therapies Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company.

Therapies 52

Therapies Science Treatment Disease 52

Drug Target Review

MARCH 17, 2025

However, a deeper understanding of brain function particularly the role of synaptic plasticity is now opening the door to innovative therapies. He has contributed to more than 130 granted patents and advanced over 12 clinical drug candidates across various therapeutic areas, including cognition, depression, pain and other disorders.

Treatment 52

Treatment Licensing Licensing Science 52

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

JANUARY 18, 2021

. – January 19, 2021) – Awakn Life Sciences Inc., a biotechnology company focused on research, development and delivery of psychedelic medicines for the treatment of mental health conditions, today announced the appointment of Dr. Shaun McNulty, formerly at GlaxoSmithKline (GSK), as Chief Science Officer and Prof.

Science 52

Science Clinical Trials Trials Treatment 52

DrugBank

MAY 15, 2024

The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess. This method was more about serendipity than science. But as molecular biology has advanced, so too has our approach to finding new drugs.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98